anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sepsis is a heterogeneous syndrome and phenotypes have been proposed using clinical data. Less is known about the contribution of protein biomarkers to clinical sepsis phenotypes and their importance for treatment effects in randomized trials of resuscitation. The objective is to use both clinical and biomarker data in the Protocol-Based Care for Early Septic Shock (ProCESS) randomized trial to determine sepsis phenotypes and to test for heterogeneity of treatment effect by phenotype comparing usual care to protocolized early, goal-directed therapy(EGDT). In this secondary analysis of a subset of patients with biomarker sampling in the ProCESS trial (n = 543), we identified sepsis phenotypes prior to randomization using latent class analysis of 20 clinical and biomarker variables. Logistic regression was used to test for interaction between phenotype and treatment arm for 60-day inpatient mortality. Among 543 patients with severe sepsis or septic shock in the ProCESS trial, a 2-class model best fit the data (p = 0.01). Phenotype 1 (n = 66, 12%) had increased IL-6, ICAM, and total bilirubin and decreased platelets compared to phenotype 2 (n = 477, 88%, p < 0.01 for all). Phenotype 1 had greater 60-day inpatient mortality compared to Phenotype 2 (41% vs 16%; p < 0.01). Treatment with EGDT was associated with worse 60-day inpatient mortality compared to usual care (58% vs. 23%) in Phenotype 1 only (p-value for interaction = 0.05). The 60-day inpatient mortality was similar comparing EGDT to usual care in Phenotype 2 (16% vs. 17%). We identified 2 sepsis phenotypes using latent class analysis of clinical and protein biomarker data at randomization in the ProCESS trial. Phenotype 1 had increased inflammation, organ dysfunction and worse clinical outcomes compared to phenotype 2. Response to EGDT versus usual care differed by phenotype.
Hyperbaric oxygen (HBO2) at 1.5 atms. Stratified by site and time from injury (less than one year versus one year or more), in which participants are randomized. Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization.
Participants in the intervention group will receive the DBT-ST by means of a free video-communication app. Over the next 13 weeks from the baseline, the intervention group will receive a weekly 120-minute internet-based DBT-ST focusing on the four modules of DBT-ST.
A method creates protocols. A protocol condition object is selected from a graphical user interface displaying a plurality of different protocol condition objects. Each object is associated with at least one corresponding parameter requirement. The selected protocol condition object is displayed in a protocol sequence window of the graphical user interface. A specific parameter window related to the corresponding parameter requirement for the selected object may be displayed. The method receives a specific parameter related to the corresponding parameter requirement within the specific parameter window. A clinical protocol having a condition as a function of the received specific parameter for the selected protocol condition type is generated.
A method for producing an pharmaceutical extrudate (101) comprising a low dose active pharmaceutical ingredient in which an extrusion material is conveyed by an extruder screw (102) of a screw extruder device (100) from a feeding section (103) of the screw extruder device (100) to an output section (108) of the screw extruder device (100). An extrusion liquid (109) is pumped with a predetermined volumetric flow rate, wherein the extrusion liquid (109) comprises a carrier solution in which a dosed quantity of the active pharmaceutical ingredient is suspended, dissolved or melted. The extrusion liquid (109) is added to the extrusion material within an injection section (106) of the screw extruder device (100). The extrusion liquid (109) is mixed with the extrusion material within a mixing section (107) of the screw extruder device (100) to produce the pharmaceutical extrudate (101). The pharmaceutical extrudate (101) is outputted at the output section (108) of the screw extruder device (100). The carrier solution may be polyethylene glycol and distilled water. The preferred active ingredient is ibuprofen. A production system for producing a pharmaceutical extrudate is also claimed.
The present invention relates to nucleic acid molecules encoding polypeptides which have amino acid sequences of the voltage-gated chloride channel CIC-2, wherein the glycine (Gly) residue corresponding to position (715) of the wild-type voltage-gated chloride channel CIC-2 is replaced by another amino acid residue or wherein amino acids corresponding to positions (74 to 117) of the wild-type voltage-gated chloride channel CIC-2 are deleted or wherein the wild-type translational reading frame of the voltage-gated chloride channel CIC-2 is altered due to an insertion of a nucleotide residue between position (596 and 597) of the corresponding wild-type nucleotide sequence. The invention further relates to polypeptides encoded by said nucleic acids, vectors and hosts comprising said nucleic acid molecules as well as to methods for producing polypeptides encoded by said nucleic acid molecules. The present invention also provides antibodies specifically directed to polypeptides encoded by said nucleic acid molecules. Additionally, primers for selectively amplifying said nucleic acid molecules are provided in the present invention as well as kits, compositions, particularly diagnostic compositions comprising said nucleic acids, vectors, polypeptides, antibodies and/or primers are provided. Also pharmaceutical compositions comprising nucleic acids encoding a functional voltage-gated chloride channel are provided. Moreover, the present invention relates to methods of diagnosing neurological diseases associated with the presence of any one of the aforementioned nucleic acids or polypeptides encoded therefrom as well as to uses and methods for treating neurological disorders/diseases employing a functional voltage-gated chloride channel CIC-2. Furthermore, the present invention also relates to methods for identifying molecules which are capable of specifically interacting with or altering the characteristics of the polypeptides of the invention as well as to methods for the production of pharmaceutical compositions.
Single doses of naldemedine up to 100 mg (500 times the recommended dose) and multiple doses of up to 30 mg (150 times the recommended dose) for 10 days have been administered to healthy subjects in clinical studies. Dose-dependent increases in gastrointestinal-related adverse reactions, including abdominal pain, diarrhea, and nausea, were observed.

Single doses of naldemedine up to 3 mg (15 times the recommended dose) and multiple doses of 0.4 mg (twice the recommended dose) for 28 days have been administered to patients with OIC in clinical studies. Dose-dependent increases in gastrointestinal-related adverse reactions, including abdominal pain, diarrhea, nausea, and vomiting, were observed. Also, chills, hyperhidrosis, and dizziness were reported more frequently at 1 and 3 mg doses and hyperhidrosis at the 0.4 mg dose.

No antidote for naldemedine is known. Hemodialysis is not an effective means to remove naldemedine from the blood [see Clinical Pharmacology (12.3)].
The invention relates to PCV2 immunogenic compositions and methods of producing such compositions. An improved method for recovering the protein expressed by open reading frame (2) from porcine circovirus type (2) is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame (2) coding sequences into cells contained in growth media, causing the virus to express open reading frame (2), and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time consuming extraction procedures required to separate and recover the recombinant protein from within the cells. The invention further relates to containers and pill cases containing the proteins or the immunogenic compositions.
EXALGO is not for use in women during and immediately prior to labor, where shorter acting analgesics or other analgesic techniques are more appropriate [see Indications and Usage (1)]. Occasionally, opioid analgesics may prolong labor by temporarily reducing the strength, duration, and frequency of uterine contractions. However, these effects are not consistent and may be offset by an increased rate of cervical dilatation which tends to shorten labor.

Opioids cross the placenta and may produce respiratory depression and psychophysiologic effects in neonates. Closely observe neonates whose mothers received opioid analgesics during labor for signs of respiratory depression. An opioid antagonist, such as naloxone, should be available for reversal of opioid-induced respiratory depression in the neonate in such situations.
Hemorrhagic shock (HS) is accompanied by a pronounced activation of the inflammatory response in which acute lung injury (ALI) is one of the most frequent consequences. Among the pivotal orchestrators of this inflammatory cascade, extracellular cold-inducible RNA-binding protein (eCIRP) emerges as a noteworthy focal point, rendering it as a promising target for the management of inflammation and tissue injury. Recently, we have reported that oligonucleotide poly(A) mRNA mimic termed A 12 selectively binds to the RNA binding region of eCIRP and inhibits eCIRP binding to its receptor TLR4. Furthermore, in vivo administration of eCIRP induces lung injury in healthy mice and that mouse deficient in CIRP showed protection from inflammation-associated lung injury. We hypothesize that A 12 inhibits systemic inflammation and ALI in HS. To test the impacts of A 12 on systemic and lung inflammation, extent of inflammatory cellular infiltration and resultant lung damage were evaluated in a mouse model of HS. Male mice were subjected to controlled hemorrhage with a mean arterial pressure of 30 mm Hg for 90 min and then resuscitated with Ringer's lactate solution containing phosphate-buffered saline (vehicle) or A 12 at a dose of 4 nmol/g body weight (treatment). The infusion volume was twice that of the shed blood. At 4 h after resuscitation, mice were euthanized, and blood and lung tissues were harvested. Blood and tissue markers of inflammation and injury were evaluated. Serum markers of injury (lactate dehydrogenase, alanine transaminase, and blood urea nitrogen) and inflammation (TNF-α, IL-6) were increased after HS and A 12 treatment significantly decreased their levels. A 12 treatment also decreased lung levels of TNF-α, MIP-2, and KC mRNA expressions. Lung histological injury score, neutrophil infiltration (Ly6G staining and myeloperoxidase activity), and lung apoptosis were significantly attenuated after A 12 treatment. Our study suggests that the capacity of A 12 in attenuating HS-induced ALI and may provide novel perspectives in developing efficacious pharmaceutics for improving hemorrhage prognosis.
1. A rectal suppository, comprising a lipophilic base and an active substance of natural origin, characterized in that comprises a purified naphthalane as the active substance and additionally zinc oxide with the following component weight ratio: Purified naphthalane	0.2 Zinc oxide	0.2 Lipophilic base	1.6 2. The suppository according to claim 1, characterized in that comprises cacao oil or pumpkin seed oil as the lipophilic base. 3. The suppository according to claim 1, characterized in that comprises cacao oil or pumpkin seed oil and camomile oil as the lipophilic base with the following component weight ratio to the total suppository mass: Cacao oil or pumpkin seed oil	1.4 Camomile oil	0.2 4. The suppository according to claim 1, characterized in that comprises cacao oil and pumpkin seed oil with the following component weight ratio to the total suppository mass: Cacao oil	1.4 Pumpkin seed oil	0.2 5. The suppository according to claims 1-4, characterized in that serves for the treatment and/or prophylaxis of urinological diseases. 6. The suppository according to claims 1-4, characterized in that serves for the treatment and/or prophylaxis of proctologic diseases. 7. The suppository according to claims 1-4, characterized in that serves for the treatment and/or prophylaxis chronic male inflammatory diseases. 8. A vaginal suppository, comprising a lipophilic base and an active substance of natural origin, characterized in that comprises a purified naphthalane as the active substance and additionally zinc oxide with the following component weight ratio: Purified naphthalane	0.5 Zinc oxide	0.2 Lipophilic base	1.3 9. The suppository according to claim 8, characterized in that comprises cacao oil or pumpkin seed oil as the lipophilic base. 10. The suppository according to claim 8, characterized in that comprises cacao oil or pumpkin seed oil and camomile oil as the lipophilic base with the following component weight ratio to the total suppository mass: Cacao oil or pumpkin seed oil	1.1 Camomile oil	0.2 11. The suppository according to claim 8, characterized in that comprises cacao oil and pumpkin seed oil with the following component weight ratio to the total suppository mass: Cacao oil	1.1 Pumpkin seed oil	0.2 12. The suppository according to claims 8-11, characterized in that serves for the treatment and/or prophylaxis of gynecologic diseases.
The invention provides a stable xanthophyll preparation and a preparation method thereof. According to the invention, xanthophyll is loaded into microspheres such that a stabilizing purpose is reached. A microsphere substrate is selected from starch, albumin, gelatin, chitosan, or ethyl cellulose. The xanthophyll microspheres provided by the invention are prepared through an emulsification solvent diffusion method. The xanthophyll microspheres have the advantages of round and neat appearance, no adhesion, and uniformly distributed particle size. Free xanthophyll microsphere preparation can be achieved under normal temperature. The operation is simple and feasible. With the method, a problem of raw material medicine loss during a preparation method adopting a spray-drying method is avoided.
Ganoderma is known to modulate immunity and improve health. However, the mechanism is not clear. We hypothesize that patients who have completed standard treatment with/without radiotherapy might require biological modifier such as Ganoderma to improve life quality and immunity status.

A total of 100 patients are randomized to study and control groups. In study group, Ganoderma Spores Powder Capsules are given to the patients for 6 weeks, In control group, only placebos are given during the same period. Then the patients in study and control groups are switched, Ganoderma Spores Powder Capsules and placebos are given for 6 weeks. The data pertaining to their Life quality are collected using Quality of Life Questionnaire after the first 6 weeks and the second 6 weeks. The immunity status is also studied at the same time.
This treatment arm is an 4-session training delivered in gender-segregated groups at the village level that targets couples at risk of domestic violence in separate spaces. The sessions are delivered by Community Health Volunteers: 1 Facilitator and 1 Community Agent. The training aims to raise awareness of IPV and social norms around domestic violence and is delivered at the household in a private environment. The sessions topics are: i) gender roles, beliefs and stereotypes; ii) violence, cultural patterns and human rights; iii) healthy relationships within the family; iv) good treatment between family members and self-care; v) assertive communication; vi) resolution and conflict management; vii) resources for domestic violence cases; and viii) leadership and women's agency.
Eight hundred and twelve elderly (65 years of age or older) subjects were exposed to CONZIP in clinical trials. Of those subjects, two hundred and forty were 75 years of age and older. In general, higher incidence rates of adverse events were observed for patients older than 65 years of age compared with patients 65 years and younger, particularly for the following adverse events: nausea, constipation, somnolence, dizziness, dry mouth, vomiting, asthenia, pruritus, anorexia, sweating, fatigue, weakness, postural hypotension and dyspepsia. For this reason, CONZIP should be used with great caution in patients older than 75 years of age [see Dosage and Administration (2.3)].

Respiratory depression is the chief risk for elderly patients treated with opioids and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were co-administered with other agents that depress respiration. Titrate the dosage of CONZIP slowly in geriatric patients and frequently reevaluate the patient for signs of central nervous system and respiratory depression [see Warnings and Precautions (5.12)].

Tramadol is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to regularly evaluate renal function.
OBJECTIVES: Increased sexually transmitted and blood-borne infections (STBBI) testing can reduce the burden of disease among Two-Spirit, gay, bisexual, transgender, and other queer Black, Indigenous, people of colour (2SGBTQ+ BIPOC). However, this population encounters barriers, such as discrimination, when accessing in-person STBBI testing services. Digital STBBI testing, such as self-testing/collection kits ordered online and digital requisitions, may address some of these barriers. Our aim was to understand acceptability of free digital STBBI testing among 2SGBTQ+ BIPOC living in Ontario, Canada.
DESIGN: We approached this analysis using Implementation Science and Critical Race Theory. We conducted interviews and focus groups with 21 2SGBTQ + BIPOC individuals from 2020-2021. Participants were asked about their perceptions of the benefits and drawbacks of digital STBBI testing, populations that would benefit from using these services, and recommendations for how these services may be implemented in Ontario. Interviews and focus groups were transcribed verbatim and analyzed using reflexive thematic analysis.
RESULTS: Six themes emerged. Digital STBBI testing services: (1) May reduce oppression experienced by 2SGBTQ + BIPOC when testing in-person; (2) Should address the unique needs that 2SGBTQ + BIPOC experience due to other intersecting identities they possess; (3) Should adapt their services to suit the varying cultural contexts and living circumstances of 2SGBTQ + BIPOC; (4) Should be accessible to 2SGBTQ + BIPOC who hold diverse or no documentation; (5) Should be offered in multiple languages; (6) May be inaccessible to those without Internet access or devices.
CONCLUSION: Digital STBBI testing is one strategy that may reduce discrimination experienced by 2SGBTQ + BIPOC when getting tested in-person. However, digital STBBI testing services may not address all the needs of 2SGBTQ + BIPOC. Racism and other forms of oppression embedded into in-person and digital testing services will need to be addressed to meet the needs of this diverse population.
Our study focuses on creating hybrid compounds and assessing their suitability for use in skincare products. The synergistic combination of Kojic acid, NSAIDs, and Palmitic acid proved to be an effective approach in inhibiting melanin production, making it a promising solution for individuals with hyperpigmentation concerns with Kojic acid (KA) Ibuprofen monoester (IBUM) and Ibuprofen-Kojic acid-Palmitic acid diester (IBUD) exhibiting a potential tyrosinase (38 % and 49 % inhibition at 200 µM) and anti-melanogenesis activity (77 % and 79 % inhibition at 100 µM). Furthermore, these compounds exhibited potent anti-inflammatory effects, Kojic acid-Diclofenac monoester (DICM) and Diclofenac-Kojic acid-Palmitic acid diester (DICD) offering potential benefits for inflammation by lowering the paw volume. A stability study under chemical conditions and enzymatic conditions was also performed, wherein DICM and DICD showed a better half-life of 515, 593 h under chemical stability and 6.3, 7.5 h under enzymatic stability studies respectively. The diester hybrids IBUD, DICD, Naproxen-Kojic acid-Palmitic acid diester (NAPD) showed a better permeation and penetration profiles compared to their parent drugs. In-vitro cell line studies were conducted to assess the safety and efficacy of these hybrid esters, with promising results. The dual inhibitor demonstrated minimal cytotoxicity and remarkable anti-melanogenic and anti-inflammatory activities, showing its potential as a versatile agent in addressing both melanogenesis and inflammation.
Glioblastoma multiforme is the most malignant and common, about 50%, variant of all primary brain tumours. The treatment strategies for this disease have not changed appreciably for many years consisting of a surgical intervention (biopsy or tumour resection) and post-operative local radiotherapy until several years ago. Combined chemoradiotherapy with temozolomide is at the moment the standard medical practice after results of the joint EORTC-NCIC phase III study randomizing between radiotherapy alone and combined chemoradiotherapy with temozolomide showed a significant improvement in 2-years survival from 8% to 24% for the combined treatment arm (Stupp 2005). Given the poor prognosis of these patients and the still poor treatment response, further therapeutic improvement will remain the most challenging topic for the future. The next step to further improve survival for this patient group would be the addition of biological modifying and/or antiangiogenic therapies. These strategies are motivated by the fact that glioblastomas often express very high levels of vascular endothelial growth factor which is a key mediator of blood vessel growth as high expression of EGFR, which upregulates the downstream PI3K-AKTpathway. (Fischer I, Carmeliet P, Koul D) One possible candidate is nelfinavir, a protease inhibitor interfering with Akt activity downstream of EGFR and upstream of VEGF. (Geng L, Gorski D, HLu B)
Preschool years are a critical period in which children acquire physical, mental, emotional and social skills and development progresses rapidly. Psychosocial skills are one of the most important dimensions of development. It is emphasized that there is an important relationship between psychosocial skills and health and well-being. It is reported that socially competent and social-emotionally developed children are better able to cope with stressful situations, this skill increases school readiness, academic self-efficacy and academic success, and improves peer relations and coping skills with emotions. In the literature, school-based intervention programs that facilitate children's coping with stress, enable them to respond constructively to psychological and social difficulties, and help them develop emotion regulation skills are recommended from preschool onwards. The aim of this study was to determine the effects of a psychosocial development program that includes moving music activities, exercises including yoga postures accompanied by stories, breathing techniques and self-massage practices on social-emotional well-being and psychological resilience, social competence, behavior and quality of life of preschool children.